2022 World Conference on Lung Cancer (ePosters)-EP05.01-014. Circulating Tumor DNA to Identify Genomic Biomarkers of Radiation Sensitivity in Locally Advanced Non-Small Cell Lung Cancer

EP05.01-014. Circulating Tumor DNA to Identify Genomic Biomarkers of Radiation Sensitivity in Locally Advanced Non-Small Cell Lung Cancer

Back to course

Pdf Summary

This study aimed to evaluate the feasibility of using liquid biopsy ctDNA testing to identify genomic markers of radiation therapy (RT) sensitivity and resistance in patients with locally advanced non-small cell lung cancer (NSCLC). The study included 29 patients with unresectable NSCLC who were undergoing chemoradiation therapy (CRT). Next-generation sequencing liquid biopsy profiling was performed using the MSK-ACCESS assay, which included 129 genes and paired white blood cell sequencing. The OncoKB classification system was used to classify genetic alterations as markers of RT resistance or sensitivity. <br /><br />The results showed that one patient had a marker of RT resistance detected in plasma ctDNA and developed locoregional and distant recurrence after CRT. On the other hand, markers of RT sensitivity were detected in three patients, and none of them had a local recurrence. Two of these patients were disease-free at the last follow-up, while one patient had distant disease progression. <br /><br />The study demonstrates the feasibility of using liquid biopsy to identify genomic markers of RT response, including somatic mutations associated with RT sensitivity and resistance. These findings may inform future evaluations of personalized, genomically-adjusted thoracic RT for lung cancer.

Asset Subtitle

Emily Lebow

Meta Tag

Speaker Emily Lebow

Topic Locally Advanced Non-small Cell Lung Cancer - Chemoradiotherapy and Radiotherapy

Keywords

liquid biopsy

ctDNA testing

genomic markers

radiation therapy

RT sensitivity

RT resistance

unresectable NSCLC

chemoradiation therapy

Next-generation sequencing

somatic mutations